Genitourinary Cancers | Specialty

Factors in Selecting Immunotherapy or TKI Inhibition

March 8th 2018

Metastatic RCC: Using Frontline Ipilimumab/Nivolumab

March 8th 2018

Evaluating Frontline Systemic Therapy for Metastatic RCC

March 8th 2018

Newly Diagnosed Metastatic RCC: Frontline Therapy

March 8th 2018

Perioperative RCC Treatment: Immunotherapy and Urology

March 8th 2018

RCC: Applying Adjuvant Therapy Data From Clinical Trials

March 8th 2018

Adjuvant Sunitinib's Role in the Treatment of RCC

March 8th 2018

Figlin Discusses Optimizing Expanding Treatment Options in RCC

March 8th 2018

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

March 8th 2018

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Expert Addresses Advances and Challenges in Bladder Cancer

March 7th 2018

Mark Tyson, MD, discusses the management of localized advanced bladder cancer, the promise of immunotherapy, and his advice for urologists treating patients with bladder cancer.

Dr. Kim Discusses Cytoreductive Nephrectomy in Metastatic RCC

March 7th 2018

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

FDA Approves 4-Week Nivolumab Dosing Schedule

March 6th 2018

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

Optimal Sequencing Key to Capitalizing on RCC Advances

March 6th 2018

Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

March 5th 2018

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

A Call to Arms in Urology

March 4th 2018

Prostate cancer continues to be the most common newly diagnosed solid tumor in men over 50 years and the second leading cause of cancerspecific mortality.

Dr. Tyson on Rationale For Neoadjuvant Chemotherapy in Bladder Cancer

March 3rd 2018

Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.

Dr. Singh on Patient Selection for Immunotherapy in Bladder Cancer

March 2nd 2018

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.

Dr. Ho on How Molecular Subtypes Affect Sequencing

March 2nd 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

DDR Alterations Associated With Increased Anti-PD-1/PD-L1 Activity in Bladder Cancer

March 2nd 2018

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

Dr. Figlin on the Safety Profile of Immuno-Oncology Agents in Kidney Cancer

March 1st 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the tolerability and toxicity of immune-oncology agents in kidney cancer.